An open-label, single-arm, non-randomized phase 3 study to evaluate clinical efficacy, safety, and pharmacokinetics of subcutaneous administration of human plasma-derived C1-esterase inhibitor in the prophylactic treatment of hereditary angioedema in Japanese subjects
Latest Information Update: 25 Jan 2023
At a glance
- Drugs Complement C1 inhibitor protein (Primary)
- Indications Hereditary angioedema
- Focus Pharmacokinetics; Registrational; Therapeutic Use
- Sponsors CSL Behring
Most Recent Events
- 12 Apr 2022 Status changed from active, no longer recruiting to completed.
- 06 May 2020 New trial record